Korro Bio, Inc. Employee Directory
Biotechnology ResearchMassachusetts, United States51-200 Employees
Korro Bio, Inc. is a biotechnology research company headquartered in Cambridge, Massachusetts (ZIP 02139) with a workforce of 51-200 employees and a website at korrobio.com. The company leverages RNA editing technology to perform precise single-base edits in RNA to modulate protein function, aiming to address genetic diseases by repairing underlying genetic causes. Korro Bio is developing KRRO-121 as a potential treatment for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy. In January 2026, Dr. Krishnamurthy departed from his role as Senior Vice President, Head of Platform Research, and the company also participated in industry events such as the TD Cowen Health Care Conference, where Dr. Ram Aiyar was announced to present on March 3, 2026. The company has announced a strategic collaboration with Novo Nordisk to develop genetic medicines for cardiometabolic diseases, including the development of two therapeutic candidates.